IMDX
Insight Molecular Diagnostics Inc.
NASDAQ · Healthcare · Biotechnology · US
$4.00
+1.27%Jul 16, 2026, 19:22 UTC
Insight Molecular Diagnostics Inc. highlighted a favorable new Medicare policy that expands coverage for donor-derived cell-free DNA testing in transplant care.
Source: